Depression Flashcards
3 important roles of NE
- sleep and arousal
- attention
- learning and memory
NMDA antagonist that has recent interest in use in depression
Ketamine
2 ways in which catecholamines are metabolized
- Monoamine oxidases (MAO)
2. catechol-O-methyltransferase (COMT)
Types of NE receptors
alpha and beta adrenergic metabolotropic receptors
NE pre-synaptic autoreceptor that is important in feedback inhibition
alpha2 receptor
Where the majority of neurons that synthesize serotonin are located
raphe nuclei
Serotonin receptor that is a ligand-gated ion channel
5HT3
Serotonin receptor that is a pre-synaptic auto-receptor that is important in feedback inhibition
5HT1D
Enzyme that metabolizes serotonin within the neuron
MAO
Main precursor of serotonin
tryptophan
Enzyme involved in the synthesis of both serotonin and NE
aromatic L-AA decarboxylase
3 MAO-Is that are exhibit non-selective MAO-A and B irreversible inhibition and increase synaptic 5HT, NE and DA
- Pheneizine
- Transylcypromine
- Isocarbazid
MAOI that exhibits selective MAO-A irreversible inhibition and increases synaptic DA
Selegiline TS
Cut off below which selegilline does not have dietary restrictions
6 mg
Toxicity that can occur if MAOIs are taken with tyramine-containing foods
hypertensive crisis
Drug that is used in the case of hypertensive crisis associated with MAOIs
Phentolamine
Drug is a non-selective serotonin antagonist that can be used to help reverse serotonin syndrome
cyproheptadine
5 tertiary amine TCAs that have NE > 5HT reuptake
- amitryptyline
- imipramine
- trimipramine
- clomipramine
- doxepin
Only TCA that has sig. 5HT reuptake inhibition
Clomiptamine
SSRI that has been shown to be safely used post-MI
Sertraline
3 secondary amine TCAs that have selective NE reuptake inhibition, less antimuscarinic action, less sedation, and less postural hypotension
- Desipramine
- Nortriptyline
- Protriptyline
5 patient populations to use caution with TCAs
- underlying CV disease
- seizure disorder
- angle-closure glaucoma
- urinary retention
- elderly
3 main adverse effects of TCAs
- atropine-like effects (dry mouth, blurred vision, constipation, urinary retention)
- orthostatic hypotension
- sedation
5 SSRIs
- Fluoxitine
- Paroxetine
- Sertraline
- Citalopram
- Escitalopram
Initial adult dose of citalopram
20 mg QD
Max adult dose/day of citalopram
40 mg
Initial adult dose of escitalopram
10 mg QD
Highest rate of sexual dysfunction and weight gain of the SSRIs
Paroxitine
SSRI that is pregnancy category D
Paroxitine
SSRI that has the highest rate of diarrhea
Sertraline
Initial adult dose of fluoxitine
10 mg QD
Max adult dose/day of escitalopram
20 mg
Initial adult dose of paroxitine CR
25 mg QD
Max adult dose/day of fluoxitine
80 mg
Max adult dose/day of paroxitine CR
62.5 mg
SSRI that has the longest half-life
Fluoxitine
5 SNRIs
- Duloxetine
- Venlafaxine
- Desvenlafaxine
- Milnacipran
- Levomilnacipran
SNRI that is only FDA approved for fibromyalgina, not depression
Milnacipran
Initial adult dose of duloxetine
20-30 mg BID
Max adult dose/day of duloxetine
60 mg
Initial adult dose of venlafaxine
25 mg TID or 37.5 mg BID
Max adult dose/day for venlafaxine
375 mg
Initial adult dose of venlafaxine ER
75 mg QD
Max adult dose/day of venlafaxine ER
225 mg
2 drugs that are selective serotonin reuptake inhibitors and are partial 5HT1A receptor agonist
- Vilazodone
2. Vortioxtine
2 drugs that are weak serotonin reuptake inhibitors and 5HT2A and 5HT2C receptor antagonist
- Trazodone
2. Nefazodone
Black box warning for nefazodone
Rare hepatic failure
Drug that inhibits dopamine and NE uptake
Buproprion
Initial adult dose of buproprion IR
100 mg BID
Max adult dose/day of buproprion IR
450 mg
Initial adult dose of buproprion SR
150 mg QD
Max adult dose/day of buproprion SR
400 mg
Initial adult dose of buproprion XL
150 mg QD
Max adult dose/day of buproprion XL
450 mg
Drug that is an alpha-2, 5HT2, 5HT3 and H1 antagonist
Mirtazapine
Initial adult dose of mirtazapine
15 mg QHS
Max adult dose of mirtazapine
45 mg
SEs of mirtazapine
sedation and weight gain
Neuronal growth factor that antidepressants may cause the upregulation of
BDNF (brain derived neurpotropic factor)
Transcription factor that regulates BDNF
CREB (cyclic AMP responsive element binding protein)
Typical duration of an untreated MDE
at least 6 months
Typical duration of a treated MDE
4-5 months
QIDS score that indicates no depression
0-5
QIDS score that indicates mild depression
6-10
QIDS score that indicates moderate depression
11-15
QIDS score that indicates severe depression
16-20
QIDS score that indicates very severe depression
> 20
QIDS score that indicates a response (regardless of starting score)
6-8
QIDS score that indicates remission
<6
The return of symptoms meeting full criteria within 6-12 months following remission of the index episode
Relapse
Occurrence of a new episode following 6-12 months of full and sustained remission from the index episode
Recurrence
5 most common residual symptoms
- Insomnia
- Fatigue
- Pain
- Difficulty concentrating
- Lack of interest
Max adult dose/day of sertraline
200 mg
Max adult dose/day of paroxitine
50 mg
Initial adult dose of sertraline
50 mg QD
Initial adult dose of paroxitine
20 mg QD
Main precursor of NE
Tyrosine
Where neurons that synthesize NE primarily originate from
locus ceruleus